NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, Forecast & News

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Cellular Biomedicine Group Inc (NASDAQ:CBMG) released its earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.01. The biotechnology company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.05 million. Cellular Biomedicine Group had a negative return on equity of 56.05% and a negative net margin of 17,921.62%. View Cellular Biomedicine Group's Earnings History.

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Cellular Biomedicine Group.

3 Wall Street analysts have issued 1 year price targets for Cellular Biomedicine Group's shares. Their forecasts range from $19.00 to $27.00. On average, they anticipate Cellular Biomedicine Group's stock price to reach $21.67 in the next year. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

Media headlines about CBMG stock have been trending extremely positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a news impact score of 5.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Cellular Biomedicine Group.

Cellular Biomedicine Group saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 515,500 shares, a decline of 12.0% from the October 31st total of 585,800 shares. Based on an average daily trading volume, of 36,500 shares, the short-interest ratio is presently 14.1 days. Approximately 3.7% of the company's shares are sold short. View Cellular Biomedicine Group's Current Options Chain.

Some companies that are related to Cellular Biomedicine Group include Alector (ALEC), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), SpringWorks Therapeutics (SWTX), Krystal Biotech (KRYS), Fate Therapeutics (FATE), NanoString Technologies (NSTG), Precision BioSciences (DTIL), Cortexyme (CRTX), Aerie Pharmaceuticals (AERI), BAVARIAN NORDIC/S (BVNRY), Rubius Therapeutics (RUBY), Vericel (VCEL), Twist Bioscience (TWST) and Atara Biotherapeutics (ATRA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), Adaptimmune Therapeutics (ADAP), Editas Medicine (EDIT), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), Novavax (NVAX), Viewray (VRAY), Anthera Pharmaceuticals (ANTH) and ACADIA Pharmaceuticals (ACAD).

Cellular Biomedicine Group's stock is owned by many different of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.90%), Nikko Asset Management Americas Inc. (2.90%), State Street Corp (1.13%), Russell Investments Group Ltd. (0.24%) and Barclays PLC (0.03%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

CBMG stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Cellular Biomedicine Group.

CBMG stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and State Street Corp. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBMG stock can currently be purchased for approximately $17.49.

Cellular Biomedicine Group has a market capitalization of $337.21 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-38,930,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.View Additional Information About Cellular Biomedicine Group.

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com/.

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]